BioClonetics

Early Stage

Developing a Cure for HIV

Analytics

Raised to Date: Raised: $265,300

Aggregate Commitments $

Platform

StartEngine

Start Date

01/05/2018

Close Date

11/02/2018

Min. Goal

$10,000

Max. Goal

$683,000

Min. Investment

$400

Security Type

SAFE

Funding Type

RegCF

Valuation Cap

$15,000,000

Discount Rate

0%

Rolling Commitments $

Status
Funded
Reporting Date

11/30/2018

Days Remaining
Funded
% of Min. Goal

2,653%

% of Max. Goal

39%

Likelihood of Max
Funded
Avg. Daily Raise

$881

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Location

Heath, Texas

Industry

Healthcare & Pharmaceuticals

Tech Sector

Who Should Be Interested:
Are you, or is someone you know, impacted by the devastating effects of HIV? With 1,800,000 people living with it each year, chances are you answered yes. If so, then investing in BioClonetics might be for you. They’ve created an antibody that can both target and neutralize the HIV virus, meaning that a safer and more effective treatment for HIV now exists.

The Company:
BioClonetics is on a mission to develop a cure for HIV...and they’re well their way to making it a reality. They’ve created a proprietary cell line that produces an anti-HIV antibody called CLone 3. They’ve demonstrated that Clone 3 neutralizes all clades and groups of HIV isolates, and their validating tests were conducted at four prestigious US laboratories and one Austrian one (including Harvard Medical School and Duke University). They expect to complete animal trials in the next 24 months, and they have several world-class laboratories who will assist them in those next phases. BioClonetics treatment differs from current treatments in that it is non-toxic, does not require lifetime treatment, and is much more affordable. Plus, it’s effective -- so far it’s been proven to work 100% against over 92% of all strains and viral subtypes of HIV-1.

The Bottom Line:
HIV is still one of the top causes of death worldwide. About 57% of people infected with HIV have no treatment, while the treatment the other 43% receives, antiretroviral drugs, is both toxic and expensive. BioClonetics is non-toxic, more affordable, and can help prevent HIV from spreading in the first place. In fact, with BioClonetics, we might just be able to fight HIV -- and even end it all together.
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
BioClonetics on StartEngine
$
Platform: StartEngine
Security Type: SAFE
Valuation: $15,000,000

Follow company

Follow BioClonetics on StartEngine
View on StartEngine (Closed)
Bullish / Bearish
You're Bullish on BioClonetics on StartEngine

Thank you for your vote on BioClonetics on StartEngine

Bullish / Bearish
You're Bearish on BioClonetics on StartEngine

Thank you for your vote on BioClonetics on StartEngine